

QSP/QST Services from the DILIsym Services division of Simulations Plus

The DILIsym Services division is comprised of quantitative systems pharmacology (QSP) and toxicology (QST) experts with the knowledge and experience to build custom disease and fit-for-purpose mechanistic models. We are also fully capable of utilizing existing published or in-house models for consulting services, and we have QSP/QST platforms already developed for consulting and licensing use.



Brett Howell President

Custom QSP Platform Development

- Large disease model development to support your entire drug discovery pipeline; models can be developed and handed over to you for in-house use in a variety of forums (e.g. MATLAB, Julia, C++, etc.)
- Small fit-for-purpose model development to address your specific questions
- Development efforts can include consulting support, let our team, in collaboration with yours, develop critical presentations/reports for internal & external use



Lisl Shoda Associate VP & Director

Extension of your Internal QSP Resources

- We can use your current in-house QSP tools in collaboration with your scientists and therapeutic area specialists to expand your FTE footprint as needed
- Exploration of "what-if" questions & key parametric spaces to jumpstart and focus your team
- Training of your QSP scientists in general or specific areas to increase productivity



Scott Q. Siler CSO

Leverage Our Existing Knowledge and Experience

- Platforms & expertise available for licensing & consulting in these therapeutic areas:
 - Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): NAFLDsym®
 - Idiopathic pulmonary fibrosis (IPF): IPFsym®
 - Cardiac wound healing and fibrosis
 - Renal diseases and interplay with the cardiovascular system
 - Drug-induced liver injury from small molecules: DILIsym®
 - Drug-induced acute kidney injury: RENAsym®
 - Additional platforms for Type 2 diabetes/metabolism, Rheumatoid Arthritis (RA), hypertension, and cardiovascular disease